Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet - 25 VIP Voice Exhibitions in Energized Movies
- 3Amazon sued over 'punitive' handling of employee absences
- 4Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 5Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
- Russia accidentally destroys its only way of sending astronauts to space
- Hamas hands over another body in the Gaza Strip
- Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- Jennifer Lawrence and Josh Hutcherson to reprise their roles for new 'Hunger Games' movie 'Sunrise on the Reaping'
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Five held on suspicion of planning attack on German Christmas market
- Reports: Germany plans expansion of foreign intelligence powers
- Find Serenity: 10 Stunning Setting up camp Areas
